Clinical Trial Update: Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects [Phase 3]

View source ↗

Summary

Phase 3 study evaluating dose conversion from Mircera to three times weekly oral Vadadustat for maintenance treatment of anemia in hemodialysis patients; result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia of Chronic Kidney Disease

Drugs mentioned

• MIRCERA (METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA)
• Vadadustat (vadadustat)

Snippet

Sponsor: Akebia Therapeutics | Conditions: Anemia Associated With Chronic Kidney Disease (CKD) | Phase 3 | Status: COMPLETED | Results posted: 2025-01-15